Author's response to reviews

Title: FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with 1st line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

Authors:

Janne B Kjersem (Janne.Beathe.Kjersem@rr-research.no)
Eva Skovlund (eva.skovlund@farmasi.uio.no)
Tone Ikdahl (uxnonan@ous-hf.no)
Tormod Guren (uxtour@ous-hf.no)
Christian Kersten (Christian.Kersten@sshf.no)
Astrid M Dalsgaard (Astrid.Marie.Dalsgaard@rr-research.no)
Mette K Yilmaz (m.yilmaz@rn.dk)
Tone Fokstuen (tone.fokstuen@karolinska.se)
Kjell M Tveit (kjetve@ous-hf.no)
Elin H Kure (Elin.Kure@rr-research.no)

Version: 3
Date: 1 May 2014

Author's response to reviews: see over
Dear BMC Cancer Editor,

Thank you for giving us the opportunity to resubmit the manuscript. We have now included the trial registration date after the trial registration number for the Nordic VII trial as requested in the Materials and methods section under NORDIC VII (line 121).

Please find enclosed the revised manuscript which we hope will be acceptable for publication.

Kind regards,

Janne Beathe Kjersem on behalf of Elin Kure (corresponding author)

Department of Genetics, Institute for Cancer Research
Oslo University Hospital HF
Radiumhospital, Postboks 4953 Nydalen
0424 Oslo, Norway